The adenine base editor corrected the most common mutation associated with Stargardt disease in the ABCA4 gene with no off-target effects.

Researchers have developed a therapy to treat Stargardt disease, the most common form of inherited macular degeneration, ...

Character Biosciences, a pioneer in genetics-guided drug discovery and development, today announced a collaboration with Bausch + Lomb, a leading global eye health company, to develop innovative ...

BMO Capital downgraded 4D Molecular (FDMT) to Market Perform from Outperform with a price target of $15, down from $40. 4D-150 durability in ...

D Molecular Therapeutics reaches agreement with FDA for phase 3 trial design of DME candidate 4D-150, showing promising ...

Under the terms of the option agreement, which was signed in December 2024, Bausch + Lomb has secured the exclusive option to acquire InflammX Therapeutics during an agreed-upon option period based on ...

City Therapeutics has inked a new deal with Bausch + Lomb for a gene silencing approach to the eye disorder geographic ...

4D Molecular Therapeutics is axing two clinical programs and cutting off funds for three other assets, with resources to be ...

This year’s CES was all about AI—or at least, that was the headline. While AI is poised to change everything, its presence at the show was more theoretical than tangible.

Eggs are packed with essential nutrients, vitamins, and minerals that benefit immunity, bones, and overall health. They ...

NDAQ:FDMT) 4DMT Focuses Pipeline to Prioritize 4D-150 in Wet AMD & DME and 4D-710 in CF and Extends Cash Runway ...

Including antioxidant-rich foods such as blueberries, spinach, red bell peppers, tomatoes, kale, purple grapes, carrots, ...